- Home
- YQ vs RDHL Comparison
YQ vs RDHL Comparison
Compare YQ & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- RDHL
- Stock Information
- Founded
- YQ 2012
- RDHL 2009
- Country
- YQ China
- RDHL Israel
- Employees
- YQ N/A
- RDHL N/A
- Industry
- YQ Other Consumer Services
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- RDHL Health Care
- Exchange
- YQ Nasdaq
- RDHL Nasdaq
- Market Cap
- YQ 12.5M
- RDHL 8.6M
- IPO Year
- YQ 2020
- RDHL N/A
- Fundamental
- Price
- YQ $1.61
- RDHL $6.50
- Analyst Decision
- YQ
- RDHL
- Analyst Count
- YQ 0
- RDHL 0
- Target Price
- YQ N/A
- RDHL N/A
- AVG Volume (30 Days)
- YQ 42.9K
- RDHL 21.3K
- Earning Date
- YQ 12-11-2024
- RDHL 12-27-2024
- Dividend Yield
- YQ N/A
- RDHL N/A
- EPS Growth
- YQ N/A
- RDHL N/A
- EPS
- YQ N/A
- RDHL N/A
- Revenue
- YQ $28,507,378.00
- RDHL $3,707,000.00
- Revenue This Year
- YQ N/A
- RDHL $224.90
- Revenue Next Year
- YQ N/A
- RDHL $82.69
- P/E Ratio
- YQ N/A
- RDHL N/A
- Revenue Growth
- YQ 22.55
- RDHL N/A
- 52 Week Low
- YQ $1.48
- RDHL $6.00
- 52 Week High
- YQ $3.55
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- YQ 36.08
- RDHL 38.21
- Support Level
- YQ $1.54
- RDHL $6.00
- Resistance Level
- YQ $1.69
- RDHL $7.30
- Average True Range (ATR)
- YQ 0.18
- RDHL 0.51
- MACD
- YQ -0.01
- RDHL -0.09
- Stochastic Oscillator
- YQ 18.50
- RDHL 21.10
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.